Biotron Limited (BITRF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -3.5 Million AUD | 30.42% |
| 2023 | -5.03 Million AUD | -81.51% |
| 2022 | -2.77 Million AUD | 13.06% |
| 2021 | -3.19 Million AUD | 10.58% |
| 2020 | -3.57 Million AUD | -28.74% |
| 2019 | -2.77 Million AUD | 14.17% |
| 2018 | -3.23 Million AUD | 32.42% |
| 2017 | -4.78 Million AUD | -3.32% |
| 2016 | -4.62 Million AUD | -4.18% |
| 2015 | -4.44 Million AUD | 8.92% |
| 2014 | -4.87 Million AUD | 1.54% |
| 2013 | -4.95 Million AUD | -60.16% |
| 2012 | -3.09 Million AUD | -27.76% |
| 2011 | -2.42 Million AUD | -26.42% |
| 2010 | -1.91 Million AUD | -4.09% |
| 2009 | -1.84 Million AUD | 22.97% |
| 2008 | -2.38 Million AUD | 29.54% |
| 2007 | -3.38 Million AUD | -9.58% |
| 2006 | -3.09 Million AUD | -17.29% |
| 2005 | -2.63 Million AUD | 24.91% |
| 2004 | -3.51 Million AUD | -32.36% |
| 2003 | -2.65 Million AUD | -39.82% |
| 2002 | -1.89 Million AUD | -23.8% |
| 2001 | -1.53 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -1.06 Million AUD | 64.04% |
| 2024 Q4 | -1.06 Million AUD | 0.0% |
| 2024 FY | -5.15 Million AUD | -2.23% |
| 2024 Q1 | -685.99 Thousand AUD | 75.41% |
| 2024 Q2 | -2.96 Million AUD | -332.56% |
| 2023 FY | -5.03 Million AUD | -81.51% |
| 2023 Q2 | -2.16 Million AUD | -430.31% |
| 2023 Q1 | -409.12 Thousand AUD | 51.36% |
| 2023 Q3 | -1.39 Million AUD | 35.71% |
| 2023 Q4 | -2.78 Million AUD | -100.0% |
| 2022 Q4 | -841.2 Thousand AUD | -100.0% |
| 2022 Q3 | -420.59 Thousand AUD | 77.81% |
| 2022 FY | -2.77 Million AUD | 13.06% |
| 2022 Q1 | -968.96 Thousand AUD | 56.15% |
| 2022 Q2 | -1.89 Million AUD | -95.61% |
| 2021 Q3 | -399.01 Thousand AUD | 83.57% |
| 2021 Q1 | -1.2 Million AUD | 48.39% |
| 2021 Q4 | -2.2 Million AUD | -453.86% |
| 2021 FY | -3.19 Million AUD | 10.58% |
| 2021 Q2 | -2.42 Million AUD | -101.87% |
| 2020 Q2 | -2.07 Million AUD | -96.62% |
| 2020 Q4 | -2.33 Million AUD | -205.1% |
| 2020 FY | -3.57 Million AUD | -28.74% |
| 2020 Q1 | -1.05 Million AUD | 25.7% |
| 2020 Q3 | -764.03 Thousand AUD | 63.2% |
| 2019 FY | -2.77 Million AUD | 14.17% |
| 2019 Q4 | -1.42 Million AUD | -100.0% |
| 2019 Q3 | -710.71 Thousand AUD | -408.56% |
| 2019 Q2 | -139.75 Thousand AUD | 0.0% |
| 2019 Q1 | -139.75 Thousand AUD | 80.6% |
| 2018 Q1 | -84.66 Thousand AUD | 84.52% |
| 2018 FY | -3.23 Million AUD | 32.42% |
| 2018 Q4 | -720.45 Thousand AUD | 0.0% |
| 2018 Q3 | -720.45 Thousand AUD | -751.01% |
| 2018 Q2 | -84.65 Thousand AUD | 0.0% |
| 2017 FY | -4.78 Million AUD | -3.32% |
| 2017 Q4 | -547.06 Thousand AUD | 0.0% |
| 2017 Q3 | -547.06 Thousand AUD | 46.07% |
| 2017 Q1 | -1.01 Million AUD | -665.69% |
| 2017 Q2 | -1.01 Million AUD | 0.0% |
| 2016 Q4 | -132.49 Thousand AUD | 0.0% |
| 2016 Q2 | -1.4 Million AUD | 0.0% |
| 2016 Q1 | -1.4 Million AUD | -395.02% |
| 2016 FY | -4.62 Million AUD | -4.18% |
| 2016 Q3 | -132.49 Thousand AUD | 90.59% |
| 2015 Q4 | -284.4 Thousand AUD | 0.0% |
| 2015 Q3 | -284.4 Thousand AUD | 74.17% |
| 2015 FY | -4.44 Million AUD | 8.92% |
| 2015 Q2 | -1.1 Million AUD | 0.0% |
| 2015 Q1 | -1.1 Million AUD | -340.11% |
| 2014 FY | -4.87 Million AUD | 1.54% |
| 2014 Q3 | -250.17 Thousand AUD | 81.16% |
| 2014 Q2 | -1.32 Million AUD | 0.0% |
| 2014 Q1 | -1.32 Million AUD | -65.47% |
| 2014 Q4 | -250.17 Thousand AUD | 0.0% |
| 2013 FY | -4.95 Million AUD | -60.16% |
| 2013 Q3 | -802.37 Thousand AUD | 0.0% |
| 2013 Q4 | -802.37 Thousand AUD | 0.0% |
| 2012 FY | -3.09 Million AUD | -27.76% |
| 2011 FY | -2.42 Million AUD | -26.42% |
| 2010 FY | -1.91 Million AUD | -4.09% |
| 2009 FY | -1.84 Million AUD | 22.97% |
| 2008 FY | -2.38 Million AUD | 29.54% |
| 2007 FY | -3.38 Million AUD | -9.58% |
| 2006 FY | -3.09 Million AUD | -17.29% |
| 2005 FY | -2.63 Million AUD | 24.91% |
| 2004 FY | -3.51 Million AUD | -32.36% |
| 2003 FY | -2.65 Million AUD | -39.82% |
| 2002 FY | -1.89 Million AUD | -23.8% |
| 2001 FY | -1.53 Million AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.116% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 171.337% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.376% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 80.355% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.283% |
| Mesoblast Limited | -84.14 Million USD | 95.833% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -128.252% |
| Genus plc | 6.4 Million USD | 154.782% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 135.987% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -276.437% |
| Marizyme, Inc. | -34.08 Million USD | 89.714% |
| ContraFect Corporation | -56.88 Million USD | 93.837% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 58.011% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 23.024% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -150.077% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -22.998% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -27.454% |
| MultiCell Technologies, Inc. | -722.81 USD | -484960.113% |
| Accustem Sciences Inc. | -3.74 Million USD | 6.416% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.057% |
| EV Biologics, Inc. | -483.06 Thousand USD | -625.8% |
| Q BioMed Inc. | -3.44 Million USD | -1.754% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 199.041% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -799.983% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -33.436% |
| Biomind Labs Inc. | -1 Million USD | -247.271% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 28.148% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 47.262% |
| Skye Bioscience, Inc. | -13.67 Million USD | 74.356% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -76.496% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -11605.606% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 30.497% |
| IMV Inc. | -38.67 Million USD | 90.934% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 77.907% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -81.416% |
| GB Sciences, Inc. | -1.42 Million USD | -146.817% |
| Alpha Cognition Inc. | -9.7 Million USD | 63.876% |
| HST Global, Inc. | -140.9 Thousand USD | -2388.211% |
| CSL Limited | 3.7 Billion USD | 100.095% |
| Halberd Corporation | -75.05 Thousand USD | -4571.636% |
| Enzolytics Inc. | -2.14 Million USD | -63.164% |
| Resverlogix Corp. | -12.74 Million USD | 72.499% |
| Affymax, Inc. | -15.04 Million USD | 76.698% |
| SYBLEU INC | -149.18 Thousand USD | -2250.223% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -10.662% |
| argenx SE | -425.04 Million USD | 99.175% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.684% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -235.83% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -121.993% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -2.969% |
| AVAX Technologies, Inc. | 6.69 Million USD | 152.385% |
| Zenith Capital Corp. | -8.94 Million USD | 60.795% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.157% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -20025.498% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -42.795% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1944.238% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.622% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -20.847% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -256.288% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -88.056% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -179.145% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -74.887% |
| BioStem Technologies, Inc. | -7.77 Million USD | 54.929% |
| ONE Bio Corp. | 13.68 Million USD | 125.626% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1831.875% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -162.542% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -211.676% |
| Agentix Corp. | -1.37 Million USD | -155.589% |
| LadRx Corporation | -3.82 Million USD | 8.305% |
| Cell Source, Inc. | -4.32 Million USD | 18.941% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -743.86% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -410.381% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -410.381% |
| NovAccess Global Inc. | -2.46 Million USD | -42.132% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -20.094% |
| Itoco Inc. | -919.14 Thousand USD | -281.45% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 17.279% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -213.321% |
| Kadimastem Ltd | -3.04 Million USD | -15.322% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1239.593% |
| CytoDyn Inc. | -18.05 Million USD | 80.584% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -13829.531% |
| Mobile Lads Corp. | -554.55 Thousand USD | -532.236% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1493.1% |
| Qrons Inc. | -643.67 Thousand USD | -444.693% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -520.847% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -57.231% |
| Rebus Holdings, Inc. | -664 Thousand USD | -428.022% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -93.031% |
| International Stem Cell Corporation | -663 Thousand USD | -428.818% |
| Bioxytran, Inc. | -3.82 Million USD | 8.222% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6560.454% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -17137.281% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 90.332% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -116.691% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -376.474% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -12.699% |
| Neutra Corp. | -229.48 Thousand USD | -1427.789% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 80.01% |
| PureTech Health plc | -146.19 Million USD | 97.602% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 83.686% |
| IXICO plc | -1.43 Million USD | -143.985% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 63.059% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.122% |
| CSL Limited | 3.81 Billion USD | 100.092% |
| Cellectis S.A. | -108.85 Million USD | 96.779% |